01.15.25
Drug discovery efforts are producing promising antiviral compounds and academic innovation is the key
READDI-AC Program Manager, Dr. Ava Vargason, discusses the critical role of academic research in antiviral drug discovery.
12.12.24
Antiviral Researchers at University of North Carolina at Chapel Hill READDI Speed Drug Discovery with CDD Vault
11.26.24
Novel oral drug in READDI-AC halts SARS-CoV-2 replication and improves outcomes in preclinical studies
09.09.24
READDI-AC researchers describe a novel protease inhibitor of Chikungunya virus with potent antiviral activity in PNAS
08.04.24
Discovery Core Director, Dr. Cheryl Arrowsmith, recognized for exceptional scientific achievements
08.01.24
Enanta Pharmaceuticals clinical-stage inhibitor, EDP-235, suppresses SARS-CoV-2 replication and transmission in vivo
06.20.24
READDI-AC researchers partner with Gilead to describe mechanism of cyano-modified nucleotide analogs that inhibit key respiratory virus RNA polymerases
05.22.24
READDI-AC researchers show broad-spectrum activity of GS-5245, an orally bioavailable RdRp inhibitor
11.14.23
Member Highlight: Dr. Colleen Jonsson Secures $11.9 Million Award for Operational Upgrades to Regional Biocontainment Laboratory
08.13.23
Can we predict the next pandemic? New research from READDI-AC explores forecasting and prevention of viral outbreaks
07.11.23
The U.S. scientist at the heart of COVID-19 lab leak conspiracies is still trying to save the world from the next pandemic
04.12.23
READDI-AC members at Wisconsin, Tennessee develop antiviral that protects against deadly Venezuelan Equine Encephalitis Virus in preclinical models
07.07.22
READDI researchers publish model of “long COVID” and explore antiviral and antifibrotic treatment options
07.05.22
Researcher Highlight: A conversation on using chemical probes to study protein function in cells and organisms in Nature Comms
06.10.22
Researcher Highlight: Katherine Seley-Radtke’s innovative “fleximer” research contributes to READDI-AC drug discovery efforts
